| You
are here: Home: BCU 4|2003: A
CME Audio Series and Activity
Breast Cancer Update: A CME Audio Series and Activity
STATEMENT OF NEED/TARGET AUDIENCE
Breast cancer is one of the most rapidly evolving fields in medical oncology.
Published results from a
plethora of ongoing clinical trials lead to the continuous emergence of new
therapeutic agents and
changes in the indications for existing treatments. In order to offer optimal
patient care — including the
option of clinical trial participation — the practicing medical oncologist
must be well-informed of these
advances. To bridge the gap between research and patient care, Breast Cancer
Update uses one-on-one
discussions with leading oncology investigators. By providing access to the
latest research
developments and expert perspectives, this CME program assists medical oncologists
in the formulation
of up-to-date clinical management strategies.
GLOBAL LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Critically evaluate the clinical implications of emerging clinical trial
data in breast cancer treatment.
- Describe and implement an algorithm for HER2 testing and treatment of
HER2-positive breast cancer
patients in your practice.
- Develop and explain a management strategy for treatment of ER-positive
breast cancer in the adjuvant,
neoadjuvant and metastatic settings.
- Develop and explain a management strategy for treatment of ER-negative
breast cancer in the adjuvant,
neoadjuvant and metastatic settings.
- Counsel ER-positive, postmenopausal patients about the risks and benefits
of aromatase inhibitors in the
adjuvant setting.
- Evaluate the emerging data on dose-dense chemotherapy and explain its
relevance to patients.
Issue 4, 2003, of Breast Cancer Update consists of discussions
with four research leaders on a variety
of important topics including neoadjuvant endocrine therapy,
adjuvant trastuzumab clinical trials,
ovarian ablation and aromatase inhibitors in premenopausal
women and the impact of clinical research
on breast cancer treatment paradigms.
SPECIFIC LEARNING OBJECTIVES FOR ISSUE 4
Upon completion of this activity, participants should be able
to:
- Consider the use of neoadjuvant endocrine therapy in patients with locally
advanced, ER-positive breast
cancer.
- Evaluate the data on carboplatin/paclitaxel/trastuzumab, and consider
utilizing this regimen in women with
HER2-positive metastatic disease.
- Describe planned and ongoing clinical trials utilizing capecitabine combinations
in the metastatic setting.
- Consider the potential benefit of zoledronic acid and goserelin in combination
with tamoxifen or
anastrozole when treating women with these agents.
ACCREDITATION STATEMENT
NL Communications is accredited by the Accreditation
Council for Continuing Medical Education to
provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
NL Communications, Inc designates this educational
activity for a maximum of 3.25 category 1 credits
towards the AMA Physician’s Recognition Award.
Each physician should claim only those credits
that he/she
actually spent on the activity.
|
